Kornimate/medical-research-clean huggingface dataset:
efficacy of mitomycin c in endoscopic dacryocystorhinostomy: a systematic review and meta-analysis

Conditions: Dacryocystitis

Summary: to assess the efficacy and safety of local application of intraoperative mitomycin c (mmc) at osteotomy site in endoscopic dacryocystorhinostomy(en-dcr).

mitomycin c (mmc) is an antineoplastic agent that inhibits the synthesis of dna, cellular rna, and protein by inhibiting the synthesis of collagen by fibroblasts. mmc was originally used as a systemic chemotherapeutic agent, it has been widely used in ophthalmic practice both intraoperatively and postoperatively for prevention of pterygium recurrence, enhancing the success rate of glaucoma filtration surgery. recently, use of mmc has been described in lacrimal drainage surgery. it is postulated that adjunctive use of mmc over the osteotomy site in endoscopic dacryocystorhinostomy(en-dcr)surgery could inhibit scarring and granulation tissue formation around the osteotomy site or common canaliculus and enhance the success of en-dcr surgery. many controlled trials have investigated adjunctive mmc for primary or revision en-dcr to augment the surgical success rate, but the results are not completely consistent. to the best of our knowledge, there was no meta-analysis on comparison of success rate of en-dcr with mmc (mmc group) and endoscopic dacryocystorhinostomy without mmc (control group). therefore, the aim of this study was to undertake systematic review and meta-analysis to evaluate the efficacy of intraoperative mmc application in en-dcr surgery and help ophthalmologists to determine whether it is a useful adjuvant in en-dcr surgery.

Eligibility criteria:
inclusion criteria: 1. comparative studies; 2. adult patients (\> 18 years) with nldo undergoing primary or revision en-dcr; 3. all studies included were required to provide the success rates of both mmc and control groups, and the followed up time was more than 6 months. exclusion criteria: 1. studies which did not provide the success rates; 2. studies which included pediatric cases.

Keywords: endoscopic dacryocystorhinostomy mitomycin c
eplerenone for the treatment of central serous chorioretinopathy

Conditions: Central Serous Chorioretinopathy

Summary: to test the effect oral eplerenone versus placebo in patients with central serious chorioretinopathy .

to evaluate the effect of oral eplerenone compared to placebo in patients with central serous chorioretinopathy (cscr) on sub-foveal (small part of retina) fluid using optical coherence tomography (oct).

Eligibility criteria:
inclusion criteria: * age 18 and over * ability to give written informed consent * sub-retinal fluid under fovea seen on oct * diagnosis of central serous chorioretinopathy (cscr): classification is at the discretion of the investigator, but general guidelines are 1. acute- first episode or symptoms less than one month prior to presentation 2. chronic- previously documented sub-foveal fluid, any prior treatment, symptoms for over 3 months, or \<50% reduction in fluid thickness on oct after 3 months. exclusion criteria: * age under 18 * impaired decision-making ability * at initial laboratory screening serum potassium \>5.5 milliequivalent (meq)/l * at initial laboratory screening serum creatinine \>2 mg/dl in men and \>1.8 mg/dl in women or decreased renal function by creatinine clearance less than 50 ml/min * absence of sub-foveal fluid * any patient with prior treatment for cscr within 3 months of enrollment * patients taking potassium supplements or potassium-sparing diuretics spironolactone, amiloride, and triamterene and/or potent cyp3a4 (cytochrome) inhibitors (amifostine, cyclosporine, fluconazole, itraconazole, ketoconazole, mifepristone, posaconazole, potassium salts, rituximab, tacrolimus, voriconazole nefazodone, troleandomycin, clarithromycin, ritonavir, and nelfinavir) * women who are pregnant or are actively trying to conceive * patients with type 1 or type 2 diabetes

Keywords: central serous chorioretinopathy csr cscr eplerenone vision choroid retina acute chronic
evusheld japan pms_japan post-marketing surveillance (pms)

Conditions: SARS-CoV-2 Infection

Summary: to investigate intends to evaluate the incidence of adverse drug reactions (adrs) in individuals who receive evusheld in clinical practice to determine its post-marketing safety profile in japanese.

to investigate intends to evaluate the incidence of adverse drug reactions (adrs) in individuals who receive evusheld in clinical practice to determine its post-marketing safety profile in japanese. the investigation will be conducted as the addtional pharmacovigilance activitiy specified in the japan risk management plan (j-rmp) of evusheld in compliance with the ministerial ordinance on good post-marketing study practice (gpsp ordinance) and for the purpose of application for re-examination under article 14-4 of the act on securing quality, efficacy and safety of products including pharmaceuticals and medical devices (pmd act).

Eligibility criteria:
inclusion criteria: * for treatment of symptomatic disease caused by sars-cov-2 infection; patients with risk factors for severe sars-cov-2 infection who do not require supplemental oxygen. * for prevention of symptomatic disease caused by sars-cov-2 infection; individuals for whom sars-cov-2 vaccination is not recommended or those who are considered to have an inadequate response to a covid-19 vaccine due to immunodeficiencies and who is not close contacts such as family members or other people living in the same dwelling as patients infected with sars-cov-2. exclusion criteria: * none
stepped surgery in uveitic cataract: a novel approach to a quiet eye

Conditions: Outcome of Stepped Cataract Surgery in Uveitis

Summary: this study aims to assess the short-term results of primary phacoemulsification and secondary posterior chamber intraocular lens (pciol) implantation in patients with uveitis.


Eligibility criteria:
inclusion criteria: * the study will include any uveitic patients below 45 years old with complicated cataract and their best corrected visual acuity (bcva) not better than 6/36 nor worse than hand movement exclusion criteria: * the study will not include those with visual acuity more than 6/36 or patients with active uveitis or with posterior segment pathology discovered by ultrasonography that may affect to a lager extent the visual prognosis
addressing patients' expectations of total knee arthroplasty in a randomized trial

Conditions: Knee Osteoarthritis; Arthroplasty, Replacement, Knee

Summary: the goals of this study are to develop and test an educational intervention to address patients' expectations of long-term outcomes of total knee arthroplasty.

the first goal of this study is to develop an educational intervention to address patients' expectations of long-term outcomes of total knee arthroplasty. the intervention will be structured according to the expectations listed in the hospital for special surgery total knee replacement expectations survey. the second goal is to test the intervention in a randomized trial. an additional goal is to compare patients' self-reported knee symptoms with radiographic findings.

Eligibility criteria:
inclusion criteria: * patients will be eligible for this study if they are 40 years of age or older and are scheduled for primary total knee arthroplasty at the hospital for special surgery. exclusion criteria: * patients will be excluded from this study for the following reasons: if they are not fluent in english; if they are not going to attend the preoperative knee replacement class; if they are unable to complete the surveys; if they refuse to participate.

Keywords: knee arthritis total knee arthroplasty expectations education
the opti study in spain looks at the history flare-ups in patients with chronic obstructive pulmonary disease (copd) treated with inhaled steroids.

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: this non-interventional, descriptive, cross-sectional cohort and multicentre study will be conducted with copd patients attended at spanish primary care offices.


Eligibility criteria:
inclusion criteria: 1. written informed consent prior to participation 2. female and male patient ≥ 40 years of age 3. chronic obstructive pulmonary disease (copd) diagnosis more than 2 years before the study visit 4. previously confirmed chronic obstructive pulmonary disease (copd) diagnosis (post-bronchodilator fev1/fvc ratio \<70%) 5. clinical data available 2 years before the study visit 6. ability to complete cat - copd assessment test exclusion criteria: 1. current participation in any clinical trial involving a drug or device 2. a moderate or severe exacerbation (requiring oral corticosteroid, antibiotics or hospitalisation) during the study visit or within 4 weeks before the study visit
daily undulating periodization methods with parkinson's disease

Conditions: Parkinson Disease; Weight-Lifting Exercise Program

Summary: compare periodized (cyclic) resistance training with and without motor training specific to activities of daily living.

this study will look at how well two different daily undulating training programs (hypertrophy-strength-power training, versus strength-power-functional training) improve participants' physical functions. all testing procedures will take place at the max orovitz laboratory on the coral gables campus. this study will involve a 1-week baseline testing phase, a 2-week familiarization phase, a 9-week intervention phase, and a 1-week post-testing window where subjects must report to the lab for 2 sessions.

Eligibility criteria:
inclusion criteria: * hoehn \& yahr classification of disability, stage 1-3 * can ambulate with or without an assistive device for at least 50 feet * able to get up and down from the floor with minimal assistance * has a score of 24 or above on the folstein mini-mental state exam exclusion criteria: * greater than stage 3 on the hoehn \& yahr classification of disability * decline in immune function such as pneumonia or systemic infection * progressive degenerative disease besides pd * spinal fusion or other orthopedic surgery in the past six months * mental disease/psychosis such as dementia * greater than minimal assistance required for gait and transfers * inability to make regular time commitments to the scheduled training sessions * participation in resistance training on a regular basis within the past six months * inability to provide consent * pregnancy * a prisoner
pediatric post-operative abdominal wound dehiscence in association with midline vs other incisions: a prospective cohort study

Conditions: Wound Dehiscence; Incision

Summary: this study is designed to see different abdominal incisions complication among neonates, infants and children and to find risk factors for developing wound dehiscence


Eligibility criteria:
inclusion criteria: -all abdominal surgeries patient under 18-year-old. exclusion criteria: * umbilical hernia, redo laparatomy, laparoscopic surgery.

Keywords: abdominal wound dehiscence, burst abdomen, pediatric abdominal incisions, children
psychophysiological correlates of mindfulness based cognitive therapy (mbct) in recurrent depression

Conditions: Depression

Summary: the study investigates cognitive attention, rumination and psychophysiological (eeg) processes in healthy subjects and remitted patients with at least three previous depressive episodes. the investigators expect that mindfulness based cognitive therapy prevents future depressive episodes and has influence on cognitive and psychophysiological measures.


Eligibility criteria:
inclusion criteria: * recurrent depression with at least 3 previous md-episodes, currently remitted (no symptoms) exclusion criteria: * current depression * lifetime schizophrenia * bipolar or schizoaffective disorder * any neurological disorders * other psychopathology during last 3 years

Keywords: recurrent depression, mindfulness training attention evoked eeg potentials relapse prevention in recurrent depression
a study of ly3209590 in participants with type 2 diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: this study will evaluate the safety and tolerability of ly3209590 when given by injection under the skin to participants with type 2 diabetes. it will also investigate how the body processes the study drug and the effect of the study drug on blood sugar levels. information about any side effects will be documented. this study will last approximately 17 weeks, not including screening. screening is required within 4 weeks prior to the start of the study.


Eligibility criteria:
inclusion criteria: * participants with type 2 diabetes mellitus (t2dm) for at least 1 year * have a glycated hemoglobin (hba1c) greater than or equal to (≥) 7.0 percent (%) to less than or equal to (≤) 10.5% at screening * have had no episodes of severe hypoglycemia in the past 6 months * are on stable basal insulin (neutral protamine hagedorn insulin suspension \[nph\] insulin, insulin glargine \[u100 or u300\], or insulin detemir) with or without metformin, dipeptidyl peptidase iv (dpp-iv) inhibitors, sulfonylureas, and sodium-glucose co-transporter 2 (sglt-2) inhibitors, at a stable dose for at least 3 months before screening exclusion criteria: * have significant lipohypertrophy in the target abdominal injection * have a history of renal impairment * have a history of deep vein thrombosis of the leg or repeated episodes of deep leg vein thrombosis in first-degree relatives (parents, siblings, or children) * have proliferative retinopathy or maculopathy and/or severe neuropathy * any significant changes in insulin regimen and/or unstable blood glucose control within the past 3 months prior to screening * require daily insulin treatment less than (\<) 0.15 unit/kilogram (u/kg) per body weight * are treated with a continuous subcutaneous insulin infusion (csii) pump * currently receiving degludec insulin therapy, or have been treated with degludec within the past 90 days
contribution of f-18 fluoro-deoxy-glucose pet/ct (positron emission tomography) to the assessment of hcc (hepato-cellular carcinoma) treatment efficiency

Conditions: Hepatocellular Carcinoma

Summary: hcc (hepato-cellular carcinoma) is the fifth most frequent cancer in humans and its prevalence is growing. the most effective treatment of hcc is surgical and includes resection and liver transplantation; however, only 20% of the patients can be treated surgically. local interventional therapy, such as radiofrequency (rf) ablation and transarterial embolization is also used. recurrence rate is very high, and extrahepatic disease develops in about 30% of the cases and in up to 20% after liver transplantation. systemic treatment is thus an option. sorafenib (multi-kinase inhibitor) is the first agent to significantly improve the overall survival in advanced hcc. however, the drug has serious side effects and is very expensive. pet/ct with f18-fdg is a common tool for systemic evaluation and staging of various tumors. the value of the fdg pet for evaluation of hcc is controversial, in particular due to the unique metabolic pathway of glucose in the hcc cells. since 2007 more and more studies suggest the feasibility of fdg pet/ct for monitoring local recurrence (especially after rf) and metastatic spread of hcc, including detection of active disease only suspected by afp (alphafoetoprotein) elevation. early detection of treatment response to therapy by whole body fdg pet/ct allows for change of treatment as early as possible,when the tumor is non-responsive before serious side effects appear or before depletion of body resources. the aim of our study is to investigate the contribution of fdg pet/ct to assessment of treatment response.


Eligibility criteria:
inclusion criteria: * advanced hcc for systemic treatment exclusion criteria: * hcc only localized in liver, * other liver disease (e.g. metastases and benign lesions)

Keywords: identification of treatment efficacy in patients with advanced hcc by pet/ct f18-fdg
effect of bilateral transcutaneous tibial nerve stimulation on postpartum constipation

Conditions: Constipation

Summary: this study will be conduct to determine the effect of bilateral transcutaneous tibial nerve stimulation on treating postpartum constipation

ttns was effective in treating constipation .it was believed that re-establishment of normal colonic function may be possible with neuromodulation of sacral nerve stimulation (sns) that may improve constipation symptoms but it is expensive and invasive . percutaneous tibial nerve stimulation (ptns) is an alternative method of neuromodulation that has shown efficacy in constipation and it stimulates l4-s3 nerve roots of sacral plexus that supply the pelvic floor and lower gastrointestinal tract, transcutaneous tibial nerve stimulation (ttns) targets the tibial nerve in a similar fashion to ptns but it is cheaper and does not require needle puncture .there were few studies showed that ttns has been used and shown to be effective for treating constipation, but till now, there is no previous study illustrating it's effect specifically on postpartum constipation. so, this study will be the first one in this issue.

Eligibility criteria:
inclusion criteria:•postpartum women, delivered by caesarean section suffering from constipation after delivery. * their ages will range from 20 to 35 years old. * their body mass index (bmi) will range from 25 to 33 kg/m2. * all participating women should have at least two criteria of rome iii diagnostic criteria for constipation. they should stop laxatives intake during treatment program - exclusion criteria: postpartum women will be excluded if they have: * history of inflammatory bowel disease, and irritable bowel syndrome. * endocrine disease or digestive tract disease. * history of genital prolapse and anal fissure. * congental anorectal malformation, stoma in situ. * diabtes mellitus and sever distal venous insuffiency. * skin eruption at the site of stimulation. * implanted pacemaker or defibrillator. * metalic implant in lower limb. * recent surgery at the lower limb. * peripheral neuropathy and neurological disorders. psychological distress.
providing oxygen during intubation in the nicu trial

Conditions: Neonatal Respiratory Failure; Tracheal Intubation Morbidity

Summary: tracheal intubation in the nicu is frequently complicated by severe oxygen desaturation. apneic oxygenation, a method of applying free flowing oxygen via nasal cannula to apneic patients undergoing intubation, prevents or delays oxygen desaturation during intubation in adults and older children. we propose to enroll patients at two sites (hospital of the university of pennsylvania and children's hospital of philadelphia) in a randomized trial in infants undergoing intubation in the nicu to determine if apneic oxygenation, compared with no respiratory support or oxygen during laryngoscopy and intubation attempts (standard care), reduces the magnitude of oxygen desaturation during tracheal intubation encounters.


Eligibility criteria:
inclusion criteria: 1. infants ≥28 weeks corrected gestational age 2. undergoing intubation in the nicu 3. pre-medication (including paralytic) administered exclusion criteria: 1. critical airway or airway anomaly 2. unstable hemodynamics (i.e. active resuscitation) 3. unable to achieve spo2 ≥90% prior to intubation attempt 4. intubation performed by non-nicu provider (i.e. anesthesiology or ent) 5. unrepaired congenital diagrammatic hernia 6. tracheal esophageal fistula within 2 weeks of repair 7. tracheostomy 8. previous enrollment in the trial 9. nasal intubation 10. covid person under investigation (pui) or covid positive 11. cyanotic heart disease 12. receiving extracorporeal membrane oxygenation support 13. conjoined twins

Keywords: apneic oxygenation tracheal intubation neonate
comparison of continuous versus intermittent enteral nutrition in critically ill patients.

Conditions: Nutrition Disorders

Summary: the purpose of the study is to compare continuous versus intermittent strategy for enteral nutrition. the study will examine if there is a difference in achieving nutritional delivery goals, tolerance and number of complications of enteral nutrition.

the study will commence following the approval by the ethics research committee. all patients admitted to our icu from the 1st of june 2018 to the 31st of may 2019 will be enrolled after fulfilling the inclusion criteria and in the absence of any exclusion criteria. informed consent will be requested. enteral nutrition will be administered via nasogastric of orogastric tube. patients will be randomised in 2 groups. in the group of patients receiving continuous feeding will be enteral nutrition administered via enteral feeding pump for at least 16 hours par day. in the group of patients receiving intermittent feeding will be enteral nutrition administered as 30-60minutes lasting bolus via enteral feeding pump 6 times per day. following the administration of the bolus the patient will be placed for 30 minutes in semi-upright sitting position. enteral nutrition requirement and composition will be standardised with the adoption of international guidelines. in 5 subsequent days from the enteral nutrition commencement will be examined if there is a difference in achieving energy and protein targets, tolerance and number of complications of enteral nutrition in between both groups. as achievement of energy and protein targets will be considered at least 80% of calculated values. the tolerance of enteral nutrition will be evaluated by the clinical examination of the abdomen, presence of diarrhoea, vomiting and the gastric residual volume of at least 0,5 liter. as the complications of enteral nutrition will be regarded the aspiration of gastric contents and ventilator associated pneumonia. nutritional status parameters will be analysed. the length of hospital stay, icu length of stay and 28-day mortality will be also monitored.

Eligibility criteria:
inclusion criteria: * age between 18 - 80 years * indication of enteral nutrition with nasogastric or orogastric tube * nutrition risk in the critically ill (nutric) score ≥5 * body mass index between 18 - 50 * mechanical ventilation expected for at least 72 hours exclusion criteria: * upper gastrointestinal tract surgery in previous medical history * bowel obstruction * bowel ischemia * acute pancreatitis * severe diarrhoea (\>1l/24hours) * gastrointestinal bleeding * short bowel syndrome * malabsorption syndrome in previous medical history * ongoing enteral nutrition on admission to icu

Keywords: critical care enteral nutrition ventilator associated pneumonia gastric residual volume